Literature DB >> 9747731

Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.

I Martínez1, J A Melero.   

Abstract

Neutralization of human respiratory syncytial virus (HRSV) by monoclonal antibodies specific for the G protein was evaluated in a microneutralization test. Only certain antibodies showed some degree of neutralization, reflected in a reduction of virus titre (10-20 times maximum), compared with negative controls. In contrast, a pool of antibodies that recognized conserved, group-specific and strain-specific epitopes showed a significant increase in virus neutralization (up to 500-1000 times). By testing binary, tertiary and quaternary combinations, four antibodies were identified which showed maximal effect in the neutralization test. These findings are discussed in terms of the location of antibody binding sites in the G protein primary structure and their relevance for HRSV neutralization and immunobiology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747731     DOI: 10.1099/0022-1317-79-9-2215

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Genetic analysis and antigenic characterization of human respiratory syncytial virus group A viruses isolated in Germany 1996-2008.

Authors:  Ortwin Adams; Judith Werzmirzowsky; Hartmut Hengel
Journal:  Virus Genes       Date:  2013-06-18       Impact factor: 2.332

3.  Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.

Authors:  U J Buchholz; H Granzow; K Schuldt; S S Whitehead; B R Murphy; P L Collins
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 4.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

Review 5.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

6.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.

Authors:  Ivy Widjaja; Oliver Wicht; Willem Luytjes; Kees Leenhouts; Peter J M Rottier; Frank J M van Kuppeveld; Bert Jan Haijema; Cornelis A M de Haan
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Authors:  Kurt A Swanson; Kara Balabanis; Yuhong Xie; Yukti Aggarwal; Concepción Palomo; Vicente Mas; Claire Metrick; Hui Yang; Christine A Shaw; José A Melero; Philip R Dormitzer; Andrea Carfi
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

10.  Need for a safe vaccine against respiratory syncytial virus infection.

Authors:  Joo-Young Kim; Jun Chang
Journal:  Korean J Pediatr       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.